BridgeBio Pharma Net Change in Property, Plant, and Equipment 2018-2025 | BBIO
BridgeBio Pharma annual/quarterly net change in property, plant, and equipment history and growth rate from 2018 to 2025. Net change in property, plant, and equipment can be defined as the overall change in capital expenditures and sales of plant, property and equipment. This field is used if a company does not report separately sales and purchases of plant, property and equipment or is calculated as the sum of purchases and sales of PP&E
- BridgeBio Pharma net change in property, plant, and equipment for the quarter ending March 31, 2025 was $0M, a 100% decline year-over-year.
- BridgeBio Pharma net change in property, plant, and equipment for the twelve months ending March 31, 2025 was $-0.003B, a 22.46% decline year-over-year.
- BridgeBio Pharma annual net change in property, plant, and equipment for 2024 was $-0.001B, a 28.56% decline from 2023.
- BridgeBio Pharma annual net change in property, plant, and equipment for 2023 was $-0.001B, a 72.91% decline from 2022.
- BridgeBio Pharma annual net change in property, plant, and equipment for 2022 was $-0.005B, a 63.6% decline from 2021.
BridgeBio Pharma Annual Net Change in Property, Plant, and Equipment
(Millions of US $) |
| 2024 |
$-1 |
| 2023 |
$-1 |
| 2022 |
$-5 |
| 2021 |
$-13 |
| 2020 |
$-8 |
| 2019 |
$-3 |
| 2018 |
$-2 |
| 2017 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$6.426B |
$0.222B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
